A new drug combination has proven promising against serious symptoms of COVID.
The combination is nafamostat and Pegasys already meets availability and efficacy requirements.
The drugs seems to stop COVID infections before they spread in people.
It ultimately suppresses the infection before it can even begin according to Professor Denis Kainov at the Norwegian University of Science and Technology’s Department of Clinical and Molecular Medicine.
This has not been tested in humans, only hamsters and cell cultures.
Nafamostat is used as a monotherapy against COVID and is being tested in Japan, while Pegasys is a hepatitis C treatment.
It appears low doses are all that are necessary to suppress the virus.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected]